Please login to the form below

Not currently logged in
Email:
Password:

Invega Trinza

This page shows the latest Invega Trinza news and features for those working in and with pharma, biotech and healthcare.

J&J files three-monthly schizophrenia drug in Europe

J&J files three-monthly schizophrenia drug in Europe

The three-monthly version was approved by the FDA as Invega Trinza in May on the back of clinical data showing that the drug was effective, preventing significant return of schizophrenic ... Xeplion/Invega Sustenna is already a big earner for J&J, with

Latest news

  • FDA approves J&J’s schizophrenia drug Invega Trinza FDA approves J&J’s schizophrenia drug Invega Trinza

    The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Recovery looks different for everyone and the long-term symptom control offered by Invega Trinza can help patients work toward their own

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics